Articles

Results 1 to 4 of 4


The Virtues of Claiming Precisely What the FDA Approved!

USA - January 3 2022 In Teva Pharms. USA, Inc. v. Corcept Therapeutics, Inc., No 21-1360 (Fed. Cir. Dec. 7, 2021), the Federal Circuit affirmed the Final Written Decision…

Adriana L. Burgy, Stacy Lewis, Melanie Magdun, Amanda K. Murphy, Sumaia Tabassum

Federal Circuit Disinfects PTAB’s Obviousness Finding for MRSA Inactivation Patent

USA - November 29 2021 The University of Strathclyde recently found relief at the Federal Circuit when a unanimous panel reversed the Patent Trial and Appeal Board’s (“the…

Thomas L. Irving, Stacy Lewis†, Amanda K. Murphy, Emma N. Ng

Predictably Part 2: Merck Overcomes Obviousness Challenge at the PTAB

USA - September 22 2021 Merck Sharp & Dohme Corp. (“Merck”) recently overcame an obviousness challenge at the Patent Trial and Appeal Board (“PTAB”) under pre-AIA law to U.S…

Adriana L. Burgy, Thomas L. Irving, Stacy Lewis

Predictably, a Funny Thing Happened on the Way to the PTAB FWD - Part 1: Merck Overcomes Inherent Anticipation Challenge at the PTAB

USA - September 21 2021 Overcoming anticipation assertions is a hurdle many patent owners face, both at examination, and later when challenged at the PTAB. Merck Sharp &…

Adriana L. Burgy, Thomas L. Irving, Stacy Lewis